This Consumer Staples name operates across more than 180 markets, selling combustible cigarettes alongside a fast-growing suite of smoke-free nicotine alternatives, including heat-not-burn devices, vapor products, and oral nicotine pouches. With a beta of just 0.40, the stock moves at less than half the pace of the broader equity market, making it a natural anchor for income-focused portfolios that prioritize stability over speculation. The 3-year dividend CAGR of 5% sits comfortably ahead of the Consumer Products industry average of 4%, signaling that management has been able to grow the payout consistently, even as the company reinvests heavily in its smoke-free transition. The business reported its strongest adjusted EPS growth since 2011 in fiscal year 2025, reflecting how the shift toward higher-margin smoke-free products is beginning to materially improve the underlying earnings profile.
The growth story here is not dependent on a single product or geography. Smoke-free alternatives now represent more than 40% of total net revenues globally, and in 27 markets they already account for more than half of all revenue, suggesting the transition is broad-based and structurally durable rather than concentrated in a few test markets. The company faces real challenges — currency headwinds from a strong US dollar, excise tax pressure in its largest single market, and intensifying competition in the oral nicotine pouch category — but these are risks that management has navigated before, and the balance sheet leverage of 2.3x net debt to EBITDA remains below the Consumer Products peer average of 2.5×.
Increasing our position in this stock within the Best Dividend Stocks Portfolio reflects the portfolio’s mandate to own companies that combine income durability with a credible long-term earnings growth story. The combination of a low-volatility return profile, consistent dividend growth, and an accelerating smoke-free revenue mix makes this a high-conviction holding for quality-focused income investors.
